fruquintinib + tislelizumab + FOLFOX
Small molecule
fruquintinib + tislelizumab + FOLFOX is one of 13 small molecule programs targeting Gastric Cancer. It is currently in development.
1
Indications
1
Total Trials
1
Active Trials
12
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
714 competitors in Gastric Cancer
#DrugCompanyPhaseTrials
1Gemzar
Johnson & JohnsonPreclinical
Ftorafur
TThe First Affiliated Hospital with Nanjing Medical University
Preclinical
S1,
CChinese Academy of Medical Sciences
Preclinical
PD-1 Inhibitor
Johnson & JohnsonPreclinical
Induction Phase1
GenmabPreclinical
Glutamine
SanofiPreclinical
Human Albumin
TTonghua Anrate Biopharmaceutical Co., Ltd.
Preclinical
CEA-Targeted CAR-T Cells
CChongqing Precision Biotech Co., Ltd
Preclinical
Cox-2 Inhibitor
SSeoul National University Hospital
Preclinical
Capecitabine, Oxaliplatin
PPeking Union Medical College Hospital
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Gastric Cancer1 trial
Fruquintinib Combined With PD-1 Inhibitor and FOLFOX as First-Line Treatment For Advanced Gastric Cancer
Not yet recruiting·SSixth Affiliated Hospital, Sun Yat-sen University·Phase 1/2·NCT06871527·44 enrolled
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]